Pharmaceutical Technology55m
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Intellia Therapeutics’ (NTLA) “Neutral” Rating Reiterated at Wedbush
Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...
Here are 71 Mass. life science firms presenting at J.P. Morgan
Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...
BMO Capital Markets Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...